CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events (CARDS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00327418|
Recruitment Status : Completed
First Posted : May 18, 2006
Last Update Posted : May 10, 2007
|Condition or disease||Intervention/treatment||Phase|
|Major Coronary Event Cerebrovascular Accident Coronary Artery Bypass Graft Angina, Unstable Revascularization||Drug: Atorvastatin||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||2800 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Double Blind Placebo Controlled Study of Atorvastatin as Prevention of CHD in High Risk Patients With Non-Insulin Dependent Diabetes Mellitus (Collaborative Atorvastatin Study - CARDS)|
|Study Start Date :||January 1997|
|Study Completion Date :||February 2004|
- Time from randomization to the occurrence of a primary clinical endpoint
- i.e. major coronary event or CABG or other coronary revascularization procedure
- or unstable angina or resuscitated cardiac arrest or stroke.
- The incidence rate of a primary clinical and endpoint; the time from randomization
- to the occurrence of and the incidence rate of other parameters e.g. total
- mortality, any cardiovascular event, new PVD etc. and the percent change from
- baseline in various lipid and lipoprotein parameters.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00327418
|Study Director:||Pfizer CT.gov Call Center||Pfizer|